Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По годам
A Fefer, M Benyunes, C Higuchi, A York, C Massumoto, C Lindgren, C D Buckner, J A Thompson
Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignanciesActa Haematol. 1993;89 Suppl 1:2-7.
A Fefer, M C Benyunes, C Massumoto, C Higuchi, A York, C D Buckner, J A Thompson
Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignanciesSemin Oncol. 1993 Dec;20(6 Suppl 9):41-5.
C Schneekloth, A Körfer, M Hadam, E Lopez Hänninen, T Menzel, A Schomburg, I Dallmann, H Kirchner, H Poliwoda, J Atzpodien
Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivoActa Haematol. 1993;89(1):13-21.
Caligiuri MA, Murray C, Robertson MJ et al.
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.J Clin Invest. 1993 Jan;91(1):123-32. doi: 10.1172/JCI116161. PMID: 7678599; PMCID: PMC330005.
G Castello, P Comella, T Manzo, M Napolitano, A P Parziale, M G Galati, A Daponte, R Casaretti, E Celentano, G Comella
Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanomaMelanoma Res. 1993 Feb;3(1):43-9.
Gratama JW, Bruin RJ, Lamers CH et al.
Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.Clin Exp Immunol. 1993 May;92(2):185-93. doi: 10.1111/j.1365-2249.1993.tb03378.x. PMID: 8485906; PMCID: PMC1554808.
J Atzpodien, H Kirchner, A Körfer, M Hadam, A Schomburg, T Menzel, M Deckert, A Franzke, M Volkenandt, I Dallmann, et al.
Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2Tumour Biol. 1993;14(6):354-9.
Jost L.M., Stahel R.A.
Interleukin-2 as single agent.The role of interleukin-2 in the treatment of cancer patients. Springer, Dordrecht. -Pp 7-28. — https://doi.org/10.1007/978-94-011-1753-1_2.
L Bergmann, K Fenchel, E Weidmann, H M Enzinger, B Jahn, D Jonas, P S Mitrou
Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II studyCancer. 1993 Sep 1;72(5):1733-42.
P A Palmer, J Atzpodien, T Philip, S Negrier, H Kirchner, H Von der Maase, P Geertsen, P Evers, E Loriaux, R Oskam, et al.
A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinomaCancer Biother. Summer 1993;8(2):123-36.
R A Figlin, W C Pierce, A Belldegrun
Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinomaSemin Oncol. 1993 Dec;20(6 Suppl 9):11-5.
Ruth Whittington, Diana Faulds
Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancerDrugs. 1993 Sep;46(3):446-514.
Vlasveld L.T., Beijnen J.H., Sein J.J. et al.
Reconstitution of Recombinant interleukin-2 (rIL-2): A Comparative Study of Various rIL-2 Muteins.European J of Cancer. 1993. 29A (14): p.1977-1979.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.